Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for Treatment of Patients with Metastatic NSCLC By Ogkologos - April 14, 2025 422 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the 3475A-D77 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Clinical Trials in Genitourinary Cancers: KEYNOTE-641, P3BEP, and PIVOT-09 August 20, 2020 GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work September 10, 2020 New Class of Compounds Rewires Cancer Cells to Self-Destruct August 29, 2023 Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... February 5, 2026 Load more HOT NEWS A Better Biomarker for Cancer Immunotherapy? Telephone-Based Rehab Program Helps People with Advanced Cancer Maintain Independence Rare Disease Day: Raising Awareness for Rare Cancers How Fatty Liver Disease Helps Cancer Thrive in the Liver
